Who are Etavopivat tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ingenol mebutate 0.015%, Ingenol Mebutate (Reference), Ingenol Mebutate (Perrigo), Ingenol Mebutate (Picato®), PEP005 (ingenol mebutate) Gel, Ingenol metabute.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etavopivat-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Etavopivat tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Etavopivat tablets (Etavopivat tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protein kinase C (PKC) activator. Area: Hematology/Rare Blood Disorders.

phase 3 Protein kinase C (PKC) activator PKC (Protein Kinase C) Hematology/Rare Blood Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Etavopivat tablets (Etavopivat tablets) — Forma Therapeutics, Inc.. Etavopivat activates the protein kinase PKC (protein kinase C) to increase fetal hemoglobin (HbF) production, thereby reducing sickling and hemolysis in red blood cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Etavopivat tablets TARGET	Etavopivat tablets	Forma Therapeutics, Inc.	phase 3	Protein kinase C (PKC) activator	PKC (Protein Kinase C)
ingenol mebutate 0.015%	ingenol mebutate 0.015%	Icahn School of Medicine at Mount Sinai	marketed	Protein kinase C (PKC) activator	Protein kinase C (PKC)
Ingenol Mebutate (Reference)	Ingenol Mebutate (Reference)	Padagis LLC	phase 3	Protein kinase C (PKC) activator	Protein kinase C (PKC)
Ingenol Mebutate (Perrigo)	Ingenol Mebutate (Perrigo)	Padagis LLC	phase 3	Protein kinase C (PKC) activator	Protein kinase C (PKC)
Ingenol Mebutate (Picato®)	Ingenol Mebutate (Picato®)	Actavis Inc.	phase 3	Protein kinase C (PKC) activator	Protein kinase C (PKC)
PEP005 (ingenol mebutate) Gel	PEP005 (ingenol mebutate) Gel	Peplin	phase 3	Protein kinase C (PKC) activator	Protein kinase C (PKC)
Ingenol metabute	Ingenol metabute	LEO Pharma	phase 3	Protein kinase C (PKC) activator	Protein kinase C (PKC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protein kinase C (PKC) activator class)

Padagis LLC · 2 drugs in this class
Actavis Inc. · 1 drug in this class
Forma Therapeutics, Inc. · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
LEO Pharma · 1 drug in this class
Peplin · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etavopivat tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/etavopivat-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing